Afya
Afya's revenue rose 11.9% to R$3.7 billion in fiscal 2025. Its operating margin was 32.8%, up from 30.6% a year earlier. Free cash flow was R$1.4 billion, up 5.4%. It paid out R$147 million in dividends and buybacks, 11% of free cash flow. The diluted share count rose 0.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
What Afya does
Afya is a medical education and technology company in Brazil. It runs medical schools and other health programs, and sells digital courses and software to students and doctors across the country. It says it has the largest medical education footprint in Brazil, based on the medical school seats approved by the education ministry (MEC).
It reports three segments. Undergraduate provides degree courses, mostly in medicine and other health sciences, at its campuses. Continuing Education sells residency preparation, specialization and graduate courses for physicians, delivered online and in person. Medical Practice Solutions sells clinical reference apps, practice management software, electronic prescriptions and financing tools for doctors. Most revenue comes from student tuition.
As of December 31, 2025, Afya had 86,025 enrolled students. It has grown partly by buying schools, including multi-discipline schools that also teach non-health subjects such as law and business, which it says are not part of its long-term plan.
Its biggest risks, as it describes them
- Brazilian rules on opening medical courses and adding seats can change and are open to court challenge.
- Hospitals and municipal schools may open medical programs under easier rules than Afya faces.
- Falling behind on updating its content and products, including with new artificial intelligence tools.
- Its dependence on tuition from medical programs, where more competition could cut growth and margins.
Income statement
From fiscal 2017 to 2025, earnings per share grew 24.7% a year and net income 42.0% a year, as new shares raised the share count by 184% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 749 | 1,093 | 553 | 911 | 1,125 |
| Debt incl. finance leases | 1,375 | 1,883 | 1,801 | 2,195 | 2,054 |
| Net debt (negative means net cash) | 626 | 790 | 1,248 | 1,284 | 929 |
| Net debt to EBITDA | 1.1x | 0.9x | 1.2x | 0.9x | 0.6x |
| Debt to equity | 0.5x | 0.6x | 0.5x | 0.5x | 0.4x |
| Interest coverage | 1.8x | 1.9x | 1.7x | 2.2x | 2.2x |
| Current ratio | 1.6x | 1.8x | 1.1x | 1.4x | 2.2x |
| Quick ratio | 1.6x | 1.8x | 1.1x | 1.4x | 2.2x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 9 | 7 of 9 | 7 of 9 |
| Rule of 40 | 55.6% | 54.1% | 48.8% |
| Altman Z'' | 2.37 | 2.85 | 3.68 |
| Accruals ratio | −8.9% | −9.8% | −8.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Pass |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 6 of 9 | 7 of 9 | 7 of 9 |
Compare
Put Afya side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Afya | FY25 | 11.9% | 32.8% | 36.9% | 16.8% | 0.6x | 7 | |
| TAL Education Group | FY26 | 33.7% | 9.2% | 16.9% | — | — | — | Compare |
| Graham | FY25 | 2.5% | 4.8% | 5.6% | 3.1% | 1.8x | 5 | Compare |
| Stride | FY26 | 4.7% | 17.9% | 17.2% | 31.3% | −0.7x | 6 | Compare |
| New Oriental Education & Technology Group | FY26 | 15.5% | 11.4% | 13.8% | 19.4% | −2.2x | 6 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 216 | 334 | 751 | 1,201 | 1,719 | 2,329 | 2,876 | 3,304 | 3,697 |
| Revenue growth | — | 54.6% | 124.8% | 60.0% | 43.1% | 35.5% | 23.5% | 14.9% | 11.9% |
| Gross profit | 92 | 166 | 442 | 766 | 1,067 | 1,470 | 1,766 | 2,089 | 2,383 |
| Research and development | — | — | — | — | — | — | — | — | — |
| Operating income | 49 | 96 | 205 | 363 | 441 | 664 | 767 | 1,012 | 1,213 |
| Net income | 45 | 86 | 154 | 292 | 223 | 374 | 386 | 632 | 752 |
| Diluted EPS (BRL) | 1.41 | 1.81 | 2.02 | 3.12 | 2.37 | 4.12 | 4.27 | 6.93 | 8.24 |
| Diluted shares (millions) | 32 | 48 | 76 | 94 | 94 | 91 | 90 | 91 | 91 |
| Cash flow | |||||||||
| Cash from operations | 40 | 80 | 299 | 372 | 631 | 844 | 1,044 | 1,433 | 1,532 |
| Capital expenditure | 17 | 19 | 57 | 90 | 126 | 168 | 118 | 137 | 166 |
| Free cash flow | 23 | 62 | 242 | 282 | 505 | 676 | 925 | 1,296 | 1,366 |
| Dividends paid | 2 | 6 | 52 | 13 | 19 | 20 | 19 | 18 | 147 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | 2 | 18 | 33 | 43 | 31 | 32 | 32 | 15 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 26 | 62 | 943 | 1,045 | 749 | 1,093 | 553 | 911 | 1,125 |
| Debt incl. finance leases | — | 78 | 60 | 618 | 1,375 | 1,883 | 1,801 | 2,195 | 2,054 |
| Total assets | — | 918 | 2,912 | 4,793 | 6,447 | 7,200 | 7,584 | 8,830 | 9,358 |
| Total liabilities | — | 328 | 799 | 1,959 | 3,447 | 3,949 | 3,942 | 4,519 | 4,467 |
| Shareholders' equity | 47 | 502 | 2,065 | 2,782 | 2,948 | 3,199 | 3,602 | 4,270 | 4,852 |
| Margins and ratios | |||||||||
| Gross margin | 42.6% | 49.7% | 58.9% | 63.8% | 62.1% | 63.1% | 61.4% | 63.2% | 64.5% |
| Operating margin | 22.8% | 28.9% | 27.3% | 30.2% | 25.6% | 28.5% | 26.7% | 30.6% | 32.8% |
| Net margin | 21.0% | 25.9% | 20.5% | 24.3% | 13.0% | 16.0% | 13.4% | 19.1% | 20.4% |
| Free cash flow margin | 10.7% | 18.5% | 32.3% | 23.4% | 29.4% | 29.0% | 32.2% | 39.2% | 36.9% |
| Rule of 40 (growth + FCF margin) | — | 73.1% | 157.1% | 83.5% | 72.5% | 64.5% | 55.6% | 54.1% | 48.8% |
| Return on capital | — | — | 20.6% | 18.4% | 12.9% | 15.9% | 16.2% | 18.5% | 16.8% |
| Return on equity | — | — | 12.0% | 12.1% | 7.8% | 12.2% | 11.4% | 16.1% | 16.5% |
| Return on assets | — | — | 8.0% | 7.6% | 4.0% | 5.5% | 5.2% | 7.7% | 8.3% |
| Net debt to EBITDA | — | 0.1x | −3.2x | −0.9x | 1.1x | 0.9x | 1.2x | 0.9x | 0.6x |